MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-03-2026
Arcturus Therapeutics Holdings Operating Cash Flow 2011-2026 | ARCT
Annual Operating Cash Flow Arcturus Therapeutics Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -74.3 M | -59.7 M | -18.1 M | 32 M | -135 M | -42.9 M | -6.44 M | -20.8 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32 M | -135 M | -40.7 M |
Quarterly Operating Cash Flow Arcturus Therapeutics Holdings
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -5.56 M | - | - | - | -35.9 M | - | -128 M | -85.9 M | -49 M | - | -92.5 M | -75.9 M | -43 M | - | -36.2 M | -20.4 M | -11.9 M | - | 1.09 M | 3.93 M | -5.41 M | - | -15 M | -8.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.93 M | -128 M | -38 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.38 | -1.08 % | $ 367 M |  Britain |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K |  USA |
 |
DBV Technologies S.A.
DBVT
|
-121 M | $ 20.52 | 0.79 % | $ 2.86 B | France |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.72 | 3.24 % | $ 8.95 B |  Australia |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.57 | -3.48 % | $ 16.1 M | USA |
 |
Forte Biosciences
FBRX
|
-50.9 M | $ 26.92 | 1.8 % | $ 349 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-12.5 M | $ 6.22 | -3.12 % | $ 178 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-60.1 M | $ 7.72 | -1.4 % | $ 489 K | USA |
 |
Galectin Therapeutics
GALT
|
-23.9 M | $ 2.24 | -12.55 % | $ 143 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Gilead Sciences
GILD
|
10 B | $ 138.79 | -0.96 % | $ 173 B | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-5.88 M | $ 0.56 | 8.45 % | $ 521 K |  Israel |
 |
Genmab A/S
GMAB
|
1.33 B | $ 27.26 | -1.77 % | $ 17.2 B |  Danmark |
 |
Gossamer Bio
GOSS
|
-171 M | $ 0.32 | -7.03 % | $ 73.1 M | USA |
 |
Grifols, S.A.
GRFS
|
597 M | $ 8.02 | -2.55 % | $ 6.83 B |  Spain |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
GT Biopharma
GTBP
|
-12.9 M | $ 0.41 | -7.26 % | $ 2.26 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
890 M | $ 88.74 | -2.78 % | $ 27.2 B | Germany |
 |
Halozyme Therapeutics
HALO
|
652 M | $ 63.49 | 0.64 % | $ 7.61 B | USA |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.62 | -3.1 % | $ 190 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-10.6 M | $ 3.32 | -6.21 % | $ 224 B | Britain |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
524 M | $ 318.56 | -3.57 % | $ 41.7 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
348 M | $ 27.62 | -0.34 % | $ 1.59 B | USA |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
iBio
IBIO
|
-15.3 M | $ 2.08 | 2.47 % | $ 21.8 M | USA |
 |
ImmuCell Corporation
ICCC
|
2.48 M | $ 6.54 | -1.06 % | $ 59 M | USA |
 |
InflaRx N.V.
IFRX
|
-39.9 M | $ 0.99 | 4.91 % | $ 152 M | Germany |
 |
Burford Capital Limited
BUR
|
181 M | $ 4.46 | -0.45 % | $ 729 M | Britain |
 |
Immutep Limited
IMMP
|
-17.6 M | $ 0.35 | -3.58 % | $ 1.08 B | Australia |